Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

COMPLETED RESEARCH: CLINICAL/TRANSLATIONAL RESEARCH
Abstract #CT06

Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Clinical Trials, Colorectal Cancer

Presenter: Axel Grothey, MD, Director, GI Cancer Research, West Cancer Center and Research Institute

Co-Authors: Scott Kopetz, MD Anderson Cancer Center, Houston, TX; Rona Yaeger, Memorial Sloan Kettering Cancer Center, New York, NY; Eric VanCutsem, University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium; Harpreet Wasan, Hammersmith Hospital, Division of Cancer, Imperial College London, London, UK; Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Fortunato Ciardiello, University of Campania Luigi Vanvitelli, Naples, Italy; Takayuki Yoshino, National Cancer Center Hospital East, Kashiwa, Japan; Kati Maharry, Pfizer, New York, NY; Janna Christy-Bittel, Pfizer, New York, NY (retired); Ashwin Gollerkeri, Pfizer, New York, NY; Josep Tabernero, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, UVic-UCC, Barcelona, Spain

Background: In the BEACON CRC study (NCT02928224), encorafenib plus cetuximab, with or without binimetinib, improved overall survival (OS) and response rate versus control (irinotecan or FOLFIRI, plus cetuximab) in patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation with disease progression after 1 or 2 regimens.1 Elevations in carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9 are linked to poorer prognosis in CRC.

Objective: To explore the relationships between CEA, CA19-9, and clinical outcomes in the BEACON CRC study.

Methods: Patients were randomized to encorafenib, binimetinib, and cetuximab (EBC; N = 224), to encorafenib plus cetuximab (EC; N = 220), or to a control group (N = 221). Blood samples for CEA and CA19-9 were taken at baseline, at day 1 of subsequent cycles, and at the end of treatment. The study assessed the associations between baseline CEA and CA19-9 levels and clinical outcomes, and the change in CEA and CA19-9 levels from baseline to cycle 2 and clinical outcomes.

Results: Tertile (T) cutoffs for baseline CEA levels were T1, ≤8 µg/L; T2, >8 µg/L to ≤66 µg/L; and T3, >66 µg/L. The median OS varied by baseline CEA tertile: T1, 17.8 months; T2, 9.5 months; and T3, 7.2 months in the EBC arm; T1, 17.7 months; T2, 9.0 months; and T3, 6.1 months in the EC arm; T1, 9.5 months; T2, 4.8 months; and T3, 4.8 months in the control arm. In the experimental arms, CEA reductions were seen at cycle 2 for patients with T2 and T3 baseline CEA (EBC T2: 56% improved [shifted to lower tertile group], 32% stayed the same [remained in same tertile group], none worsened [shifted to higher tertile group], 11% discontinued; EBC T3: 56% improved, 36% stayed the same, 8% discontinued; EC T2: 60% improved, 28% stayed the same, none worsened, 12% discontinued; EC T3: 52% improved, 32% stayed the same, 13% discontinued). In the experimental arms, for patients with T3 baseline CEA, the median OS was longer in patients with improvement versus those without improvement in CEA: 7.4 months versus 4.6 months in the EBC arm; 7.0 months versus 3.7 months in the EC arm. In all arms, patients with larger decreases in CEA levels from baseline to first tumor assessment were more likely to respond to treatment or to achieve stable disease. Baseline CEA was not associated with overall response. Similar results were observed for CA19-9 levels.

Conclusion: Among patients receiving the EBC or EC regimen, lower baseline CEA was associated with longer OS; among patients with the highest baseline CEA, reduction in CEA with treatment was associated with improved OS. The baseline CEA and early on-treatment changes in CEA and CA19-9 levels may potentially identify a subgroup of patients with a numerically greater increase in survival and improved clinical outcomes with targeted therapy for metastatic CRC with BRAF V600E mutation.

  1. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381:1632-1643.
Related Items
Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Health System Specialty Pharmacy Integration Impact on Prescription Fill Time
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Multidisciplinary Approach in Maximizing Oncology Clinic Throughput in a Comprehensive Cancer Center
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Optimization of Rasburicase Dose for the Management of Tumor Lysis Syndrome in Community Oncology Practices
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Pharmacist-Led 14-Day Oncolytic Drug Check-In Protocol
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
Safety of Rapid Dose Escalation of Venetoclax in Patients with Hematologic Malignancies
JHOP - March 2023 Vol 13 Special Feature published on March 23, 2023 in HOPA Abstracts
© Amplity Health. All rights reserved.